SAN DIEGO--(BUSINESS WIRE)--Vaxenta Biotechnologies presented at the Leonhardt Ventures Technology Showcase on January 15th in San Francisco, CA. The company provided an update on IND enabling studies in melanoma and colon cancer animal models, as well as disclosed new data on safety studies.
Leonhardt Ventures has a track record of developing and commercializing innovative technologies since 1982. The Leonhardt team pioneered cardiovascular balloon catheters in the 1980’s, stent grafts and percutaneous heart valves in the 1990’s and cardiac regenerative medicine therapies in the 2000’s. The conference showcased the Leonhardt Ventures portfolio of healthcare innovations.
About Vaxenta Inc.
Vaxenta is a biotechnology company focused on development of novel immunotherapeutic vaccines for the treatment of cancer. The company’s lead product, XenUvaX, leverages similarities between cancer and pregnancy to selectively target the three essential features of cancer: a) angiogenesis; b) metastasis; and c) immune suppression. Currently the company is in late stages of preclinical development, with plans to file an IND to the FDA in Q3 2014 for treatment of melanoma.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.